

<b>Product Name</b>	: TAK-931
<b>Synonyms</b>	: Simurosertib; TAK931
<b>Cat No.</b>	: M11316
<b>CAS Number</b>	: 1330782-76-7
<b>Molecular Formula</b>	: C <sub>17</sub> H <sub>19</sub> N <sub>5</sub> O <sub>2</sub> S
<b>Formula Weight</b>	: 341.43
<b>Chemical Name</b>	: Thieno[3,2-d]pyrimidin-4(3H)-one, 2-(2S)-1-azabicyclo[2.2.2]oct-2-yl-6-(3-methyl-1H-pyrazol-4-yl)-
<b>Description</b>	: TAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC <sub>50</sub> of <0.3 nM; prevents the initiation of DNA replication during mitosis, which causes cell cycle arrest and induces apoptosis, demonstrates antiproliferative activity with cancer cell lines and tumor growth inhibition (TGI) in murine ectopic xenograft models. Colon Cancer, Phase 2 Clinical
<b>Pathway</b>	: Angiogenesis
<b>Target</b>	: CDK
<b>Receptor</b>	: CDK
<b>Solubility</b>	: DMSO : 75 mg/mL 219.66 mM
<b>SMILES</b>	: <chem>O=C1C2=C(C=C(C3=CN=C(C3)S2)N=C([C@H]4N(CC5)CCC5C4)N1</chem>
<b>Storage</b>	: (-20°C)
<b>Stability</b>	: ≥ 2 years
<b>Reference</b>	:

1. Charles Locuson, et al. Abstract 5041: Translational pharmacokinetic-pharmacodynamic xenograft model for TAK-931, a small molecule cell division cycle 7 (CDC7) kinase inhibitor. AACR. 2. Kenichi Iwai, et al. Abstract 3073: Potential predictive biomarkers of clinical responses for a novel CDC7-selective inhibitor TAK-931. AACR.

